Abstract
X-linked agammaglobulinemia (XLA), or Brutons disease, is the most common human primary humoral immunodeficiency. XLA is caused by mutations of the Brutons tyrosine kinase (BTK), a key regulator of B-cell physiology. Since the mid 80s, substitutive therapy by intravenous gammaglobulin infusions has significantly improved XLA patient survival and quality of life. Nevertheless, some frequent affections persist despite treatment, and lead to handicapping and further to morbid clinical complications for XLA individuals. Development of gene therapy by transfer of the BTK gene into hematopoietic progenitors could represent an alternative strategy for the treatment of Brutons disease, with the advantage of a definitive cure for XLA patients. Gene therapy of XLA could be considered as a paradigm for future expansion of gene therapy approaches for many other diseases, since future utilization may be strictly dependent on a marked improvement of risk-benefit ratio compared to pre-existing treatments.
Keywords: Bruton's disease, BTK, Immunodeficiency, B-cell, Retroviral vector, Hematopoietic stem cell
Current Gene Therapy
Title: Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
Volume: 7 Issue: 4
Author(s): Thomas Moreau, Boris Calmels, Vincent Barlogis, Gerard Michel, Cecile Tonnelle and Christian Chabannon
Affiliation:
Keywords: Bruton's disease, BTK, Immunodeficiency, B-cell, Retroviral vector, Hematopoietic stem cell
Abstract: X-linked agammaglobulinemia (XLA), or Brutons disease, is the most common human primary humoral immunodeficiency. XLA is caused by mutations of the Brutons tyrosine kinase (BTK), a key regulator of B-cell physiology. Since the mid 80s, substitutive therapy by intravenous gammaglobulin infusions has significantly improved XLA patient survival and quality of life. Nevertheless, some frequent affections persist despite treatment, and lead to handicapping and further to morbid clinical complications for XLA individuals. Development of gene therapy by transfer of the BTK gene into hematopoietic progenitors could represent an alternative strategy for the treatment of Brutons disease, with the advantage of a definitive cure for XLA patients. Gene therapy of XLA could be considered as a paradigm for future expansion of gene therapy approaches for many other diseases, since future utilization may be strictly dependent on a marked improvement of risk-benefit ratio compared to pre-existing treatments.
Export Options
About this article
Cite this article as:
Thomas Moreau , Boris Calmels , Vincent Barlogis , Gerard Michel , Cecile Tonnelle and Christian Chabannon , Potential Application of Gene Therapy to X-Linked Agammaglobulinemia, Current Gene Therapy 2007; 7 (4) . https://dx.doi.org/10.2174/156652307781369128
DOI https://dx.doi.org/10.2174/156652307781369128 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Nitric Oxide and Reactive Oxygen Species in Arthritis
Current Pharmaceutical Design Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets Interferon-γ-Induced Neurotoxicity of Human Astrocytes
CNS & Neurological Disorders - Drug Targets Alphavirus Vectors for Gene Therapy Applications
Current Gene Therapy Anti-Inflammatory Effect of KW-2449 on Autoimmune Encephalomyelitis: An Experimental Study on Mice
Endocrine, Metabolic & Immune Disorders - Drug Targets Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews Immunoadjunctive Therapy against Bacterial Infections Using Herbal Medicines Based on Th17 Cell-mediated Protective Immunity
Current Pharmaceutical Design Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Magnetic Nanoparticles for MRI of Brain Tumors
Current Pharmaceutical Biotechnology Oral Tolerance in the Treatment of Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Redox Regulation and the Autistic Spectrum: Role of Tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the Amygdala
Current Neuropharmacology Therapeutic Targeting of Leukocyte Trafficking Across the Blood-Brain Barrier
Inflammation & Allergy - Drug Targets (Discontinued) Peroxisome Proliferator-Activated Receptors and the Control of Inflammation Update
Medicinal Chemistry Reviews - Online (Discontinued) The Dual Role of Interleukin-25 in the Control of Immune-Mediated Pathologies
Current Molecular Medicine Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics Microglial Proteases: Strategic Targets for Neuroprotective Agents
Current Neuropharmacology Pharmacogenomics of Multiple Sclerosis: Current Status and Potential Applications
Current Pharmacogenomics and Personalized Medicine Interleukin-21 in Immune and Allergic Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Synthetic Peptides in the Diagnosis of Neurological Diseases
Current Protein & Peptide Science The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design